Novartis, GSK, Pfizer Move To Fill Japan Void In Drugs For Rare Diseases
This article was originally published in PharmAsia News
Executive Summary
Seeing a lapse in Japan drug makers preparing for rare diseases, multinational competitors are establishing divisions in the country to develop drugs to fill local needs.